Logo image of CGM.PA

CEGEDIM SA (CGM.PA) Stock Fundamental Analysis

EPA:CGM - Euronext Paris - Matif - FR0000053506 - Common Stock - Currency: EUR

12.1  +0.1 (+0.83%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CGM. CGM was compared to 12 industry peers in the Health Care Technology industry. CGM may be in some trouble as it scores bad on both profitability and health. CGM is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CGM was profitable.
In the past year CGM had a positive cash flow from operations.
CGM had positive earnings in 4 of the past 5 years.
Each year in the past 5 years CGM had a positive operating cash flow.
CGM.PA Yearly Net Income VS EBIT VS OCF VS FCFCGM.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

1.2 Ratios

CGM's Return On Assets of 0.20% is on the low side compared to the rest of the industry. CGM is outperformed by 63.64% of its industry peers.
CGM's Return On Equity of 0.72% is on the low side compared to the rest of the industry. CGM is outperformed by 63.64% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.46%, CGM is doing worse than 63.64% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CGM is below the industry average of 7.76%.
Industry RankSector Rank
ROA 0.2%
ROE 0.72%
ROIC 2.46%
ROA(3y)1.34%
ROA(5y)1.11%
ROE(3y)4.47%
ROE(5y)3.99%
ROIC(3y)3.09%
ROIC(5y)4.03%
CGM.PA Yearly ROA, ROE, ROICCGM.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20

1.3 Margins

The Profit Margin of CGM (0.32%) is worse than 63.64% of its industry peers.
Looking at the Operating Margin, with a value of 3.16%, CGM is doing worse than 63.64% of the companies in the same industry.
In the last couple of years the Operating Margin of CGM has declined.
CGM has a Gross Margin of 18.91%. This is amonst the worse of the industry: CGM underperforms 90.91% of its industry peers.
CGM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.16%
PM (TTM) 0.32%
GM 18.91%
OM growth 3Y-24.35%
OM growth 5Y-12.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.26%
GM growth 5Y0.61%
CGM.PA Yearly Profit, Operating, Gross MarginsCGM.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

CGM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for CGM has been reduced compared to 1 year ago.
CGM has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, CGM has an improved debt to assets ratio.
CGM.PA Yearly Shares OutstandingCGM.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CGM.PA Yearly Total Debt VS Total AssetsCGM.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

CGM has an Altman-Z score of 1.19. This is a bad value and indicates that CGM is not financially healthy and even has some risk of bankruptcy.
CGM's Altman-Z score of 1.19 is on the low side compared to the rest of the industry. CGM is outperformed by 63.64% of its industry peers.
The Debt to FCF ratio of CGM is 26.87, which is on the high side as it means it would take CGM, 26.87 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of CGM (26.87) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.95 indicates that CGM is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.95, CGM is doing worse than 72.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 26.87
Altman-Z 1.19
ROIC/WACC0.67
WACC3.67%
CGM.PA Yearly LT Debt VS Equity VS FCFCGM.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 0.88 indicates that CGM may have some problems paying its short term obligations.
With a Current ratio value of 0.88, CGM is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
A Quick Ratio of 0.86 indicates that CGM may have some problems paying its short term obligations.
With a Quick ratio value of 0.86, CGM is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.86
CGM.PA Yearly Current Assets VS Current LiabilitesCGM.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CGM have decreased strongly by -79.22% in the last year.
Looking at the last year, CGM shows a small growth in Revenue. The Revenue has grown by 7.70% in the last year.
The Revenue has been growing slightly by 5.66% on average over the past years.
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.15%
Revenue 1Y (TTM)7.7%
Revenue growth 3Y7.42%
Revenue growth 5Y5.66%
Sales Q2Q%5.97%

3.2 Future

The Earnings Per Share is expected to grow by 17.32% on average over the next years. This is quite good.
Based on estimates for the next years, CGM will show a small growth in Revenue. The Revenue will grow by 5.13% on average per year.
EPS Next Y11.93%
EPS Next 2Y17.7%
EPS Next 3Y17.32%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y5.66%
Revenue Next 3Y5.13%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CGM.PA Yearly Revenue VS EstimatesCGM.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M
CGM.PA Yearly EPS VS EstimatesCGM.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2 2.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 80.67, CGM can be considered very expensive at the moment.
CGM's Price/Earnings ratio is a bit more expensive when compared to the industry. CGM is more expensive than 63.64% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 28.47. CGM is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 7.93, the valuation of CGM can be described as very cheap.
Based on the Price/Forward Earnings ratio, CGM is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
CGM's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.74.
Industry RankSector Rank
PE 80.67
Fwd PE 7.93
CGM.PA Price Earnings VS Forward Price EarningsCGM.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

CGM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CGM is cheaper than 90.91% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CGM indicates a rather cheap valuation: CGM is cheaper than 81.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.47
EV/EBITDA 4.45
CGM.PA Per share dataCGM.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CGM does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as CGM's earnings are expected to grow with 17.32% in the coming years.
PEG (NY)6.76
PEG (5Y)N/A
EPS Next 2Y17.7%
EPS Next 3Y17.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CGM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CEGEDIM SA

EPA:CGM (2/5/2025, 10:25:47 AM)

12.1

+0.1 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)10-24 2024-10-24
Earnings (Next)N/A N/A
Inst Owners19.02%
Inst Owner ChangeN/A
Ins Owners54.22%
Ins Owner ChangeN/A
Market Cap170.61M
Analysts48.89
Price Target16.35 (35.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.93%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.41%
EPS NY rev (3m)-10.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.61%
Valuation
Industry RankSector Rank
PE 80.67
Fwd PE 7.93
P/S 0.27
P/FCF 13.47
P/OCF 1.84
P/B 0.61
P/tB N/A
EV/EBITDA 4.45
EPS(TTM)0.15
EY1.24%
EPS(NY)1.53
Fwd EY12.6%
FCF(TTM)0.9
FCFY7.42%
OCF(TTM)6.57
OCFY54.31%
SpS44.96
BVpS19.76
TBVpS-11.62
PEG (NY)6.76
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.2%
ROE 0.72%
ROCE 3.34%
ROIC 2.46%
ROICexc 2.61%
ROICexgc 12.16%
OM 3.16%
PM (TTM) 0.32%
GM 18.91%
FCFM 2%
ROA(3y)1.34%
ROA(5y)1.11%
ROE(3y)4.47%
ROE(5y)3.99%
ROIC(3y)3.09%
ROIC(5y)4.03%
ROICexc(3y)3.3%
ROICexc(5y)4.28%
ROICexgc(3y)11.58%
ROICexgc(5y)15.94%
ROCE(3y)4.21%
ROCE(5y)5.49%
ROICexcg growth 3Y-24.58%
ROICexcg growth 5Y-49.29%
ROICexc growth 3Y-22.69%
ROICexc growth 5Y-16.24%
OM growth 3Y-24.35%
OM growth 5Y-12.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.26%
GM growth 5Y0.61%
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 26.87
Debt/EBITDA 2.48
Cap/Depr 92.41%
Cap/Sales 12.62%
Interest Coverage 3.39
Cash Conversion 86.93%
Profit Quality 628.08%
Current Ratio 0.88
Quick Ratio 0.86
Altman-Z 1.19
F-Score4
WACC3.67%
ROIC/WACC0.67
Cap/Depr(3y)94%
Cap/Depr(5y)98.87%
Cap/Sales(3y)12.77%
Cap/Sales(5y)13.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.15%
EPS Next Y11.93%
EPS Next 2Y17.7%
EPS Next 3Y17.32%
EPS Next 5YN/A
Revenue 1Y (TTM)7.7%
Revenue growth 3Y7.42%
Revenue growth 5Y5.66%
Sales Q2Q%5.97%
Revenue Next Year5.16%
Revenue Next 2Y5.66%
Revenue Next 3Y5.13%
Revenue Next 5YN/A
EBIT growth 1Y-28.71%
EBIT growth 3Y-18.74%
EBIT growth 5Y-7.51%
EBIT Next Year229.85%
EBIT Next 3Y55.74%
EBIT Next 5YN/A
FCF growth 1Y150.16%
FCF growth 3Y-14.47%
FCF growth 5Y-19.09%
OCF growth 1Y118.9%
OCF growth 3Y-3.91%
OCF growth 5Y-4.55%